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Methods: Patients with advanced NSCLC were divided into molecularly defined strata based on mutations in the EGFR gene, the ALK receptor tyrosine kinase gene (ALK), the KRAS gene, or the wild type of all three. All patients must have received more than two prior lines of therapy, except for those in a fifth stratum for a less pretreated EGFR cohort (EGFR<2). In the EGFR-mutant and ALK-rearranged strata, prior platinum therapy was not required. Patients with EGFR mutation must have received an EGFR tyrosine kinase inhibitor unless they had de novo resistance (e.g., T790M or exon 20 insertions). Eligible patients received weekly intravenous AUY922, 70 mg/m 2 . The primary objective was to estimate efficacy (complete or partial response, or in the absence of complete or partial response, stable disease) at 18 weeks, by the Response Criteria in Solid Tumors.
Results: A total of 153 patients from 21 global centers were enrolled from October 2010 to November 2014. The investigator-assessed overall response rate and stable disease rate at 18 weeks were 31.8% and 9.1% in the ALKrearranged stratum, 17.1% and 8.6% in EGFR-mutant stratum, 9.7% and 22.6% in the EGFR<2 stratum, 0% and 7.1% in KRAS-mutant stratum, and 8.8% and 8.8% in wildtype stratum. Biomarker data showed activity of AUY922 in EGFR-mutant patients with exon 19 deletion, T790M mutation, and exon 20 insertion. The most common (40%) all-causality adverse events were diarrhea, nausea, and decreased appetite. Visual-related disorders were reported in 79.7% of patients (most were grade 1/2). Thirty-five patients (22.9%) reported night blindness.
Introduction
Heat-shock protein90 (HSP90) is an adenosine triphosphate-dependent, molecular chaperone involved in the maintenance, maturation, and functioning of several oncogenic client proteins relevant in the pathogenesis of NSCLC. 1 Studies on resected NSCLC tumor specimens have shown that a lower expression of the gene encoding HSP90 correlates with better prognosis. 2 Inhibition of HSP90 has also been shown to induce apoptosis in NSCLC cells. 1 AUY922 is a highly potent, adenosine triphosphatecompetitive, nongeldanamycin HSP90 inhibitor. It potently inhibits growth in most NSCLC cell lines in vitro and in a variety of tumor xenografts in vivo. [3] [4] [5] [6] The first-in-human, phase 1 dose-escalation study of AUY922, which was conducted in patients with advanced solid tumors demonstrated acceptable tolerability at the recommended dose of 70 mg/m 2 . 7 These preclinical and clinical studies provided the rationale for the current phase 2 study of AUY922 in patients with advanced NSCLC with different tumor molecular etiologies.
Patients and Methods

Study Design
This was a global, multicenter, open label phase 2 study of AUY922 that was conducted in 21 global centers between October 2010 and November 2014. Patients with advanced NSCLC were divided into molecularly defined strata based on mutations in the EGFR gene, the ALK receptor tyrosine kinase gene (ALK), the KRAS gene, or the wild-type of all three. All patients must have received more than 2 prior lines of therapy, except for those in a fifth stratum for a less pretreated EGFR cohort (EGFR<2). In the EGFR-mutant and ALK-rearranged strata, prior platinum therapy was not required. Patients with EGFR mutation must have received an EGFR tyrosine kinase inhibitor (TKI) unless they had de novo resistance.
The primary objective was to estimate efficacy as assessed by the Response Criteria in Solid Tumors, classified as complete or partial response (overall response rate [ORR]) or in the absence of complete or partial response, as stable disease or no clinical benefit (NCB) for each study stratum at 18 weeks after treatment initiation. NCB is defined as development of progressive disease in within 18 weeks after the patient had started receiving treatment. Secondary objectives included assessment of overall survival (OS), progression-free survival (PFS), safety, and pharmacokinetics. An exploratory objective was included to examine molecular markers of response. Further details are provided in the Supplementary Materials and Methods.
Results
Patient Disposition and Characteristics
Of a total of 153 patients,150 were assigned to five strata, ALK-rearranged (n ¼ 22), EGFR-mutant (n ¼ 35), EGFR<2 (n ¼ 31), KRAS-mutant (n ¼ 28), and wild-type (n ¼ 34), and three patients were classified as "unknown" because the tumor tissue from them was not of a quality acceptable for molecular determination. Of the 153 patients, 151 (98.7%) discontinued treatment, most (73.2%) because of disease progression.
Baseline demographics and disease characteristics are presented in Table 1 . All patients had received one or more prior antineoplastic medications, including chemotherapy in 92.2% of patients and targeted therapy in 63.3%. Among these, four patients (2.6%), 31 (20.3%), and 40 (26.1%) received more than four, four, and three previous regimens, respectively, whereas the remaining 78 patients (51%) received one or two previous regimens. At baseline, TKIs were administered to nearly all patients in the EGFR-mutant (97.1%) and 
Efficacy
Overall, 20 patients achieved an investigatorassessed tumor response (ORR of 13.1%) and 17 patients (11.1%) had stable disease at 18 weeks. The investigator-assessed ORR and stable disease at 18 weeks among the five strata are reported in Table 2 . Most of the patients (75.8%) showed NCB, as they did not have a radiological response per the Response Criteria in Solid Tumors and progressed within 18 weeks of study treatment. Overall, on the basis of central radiological review, 15 patients (9.8%) had a radiological response, 17 patients (11.1%) had stable disease at 18 weeks, and the remainder (79.1%) showed NCB (see Table 2 ).
Bayesian analysis of the ORR and NCB rates demonstrated (1) a high probability of improved efficacy (on the basis of predefined thresholds) in the ALK-rearranged (0.899) and EGFR-mutant (0.832) strata, (2) a low probability of improved efficacy in the wildtype (0.346) and EGFR<2-mutant strata (0.185), and (3) a high probability of no efficacy in the KRAS-mutant stratum (0.036) (Supplementary Table 2 ). Three of the seven patients who had a response to treatment had received prior crizotinib-based treatment.
Next-generation sequencing data were successfully generated for 54 patients (35% because of limited tissue availability), including 11 of 31 patients (35%) assigned to the EGFR<2 stratum and 14 of 35 patients (40%) assigned to the EGFR-mutant stratum (Table 3) . Among the EGFR<2-mutant patients, seven had two mutations each (exon 19 deletions and T790M mutations [n ¼ 6] or L858R and T790M [n ¼ 1]). Among the EGFR-mutant patients who received more than two lines of therapy, 15 14 14 14 11 11 11 11 11 11 7 7 7 7 7 7 7 7 7 7 7 (Fig. 1) .
Censoring Times
In the ALK-rearranged stratum, on the basis of investigator assessment, the median PFS was 2.35 months (95% CI: 0.72-5.09) ( Fig. 2A) and the median OS was 9.53 months (95% CI: 4.07-27.73) (Fig. 2B) . In the EGFR-mutant stratum, the median PFS was 2.56 months (95% CI: 1.41-3.48) (see Fig. 2A ) and the median OS was 8.44 months (95% CI: 5.32-13.31) (see Fig. 2B ). Similarly, in the EGFR<2-mutant stratum, the median PFS was 3.68 months (95% CI: 1.64-6.64) (see Fig. 2A ) and the median OS was 14.52 months (95% CI: 11.33-25.76) (see Fig. 2B ). The median PFS times for the KRAS-mutant and wild-type strata were 1.38 (95% CI: 0.92-1.71) and 1.25 months (95% CI: 0.99-2.56), respectively (see Fig. 2A ). The overall survival times for the KRAS-mutant and wild-type strata were 4.86 (95% CI: 2.76-5.95) and 7.82 (95% CI: 4.76-16.10) months, respectively (see Fig. 2B ).
Safety
Overall, the median duration of exposure was 7.0 weeks, with a longer duration observed in the following strata: ALK-rearranged (median 11.5 weeks, 41% treated past 18 weeks), EGFR<2 (median 12 weeks, 32% treated past 18 weeks), and EGFR-mutant (median 11 weeks, 23% treated past 18 weeks). Most patients (79.7%) did not require a dose reduction, and the rates of reduction were similar across all strata. Overall, 21 patients (13.7%) discontinued treatment because of adverse events (AEs); 10 patients (6.5%) discontinued treatment because of AEs that were suspected to be related to the study drug. All patients experienced one or more AE, regardless of causality. The most common all-causality AEs (10% incidence) are summarized in Table 4 . Overall, 67.3% reported at least one grade 3 or 4 AE, regardless of causality, most frequently diarrhea (7.2%), dyspnea (7.2%), and asthenia (5.9%). The most frequently reported study drug-related AEs were diarrhea (69.9%), nausea (37.9%), asthenia (24.8%), fatigue (23.5%), night blindness (22.9%), photopsia (22.2%), and vomiting (20.9%).
Almost half of all patients (49.7%) experienced serious AEs, regardless of causality, with 16 of them (10.5%) experiencing a serious AE that was considered related to the study drug. There were no study drugrelated deaths.
Discussion
This study evaluated activity of AUY922 across a broad range of mutations (ALK, EGFR, and KRAS) in pretreated patients with advanced NSCLC. Our results show that AUY922 is active in those with ALK rearrangement and EGFR mutations. Despite preclinical evidence suggesting that KRAS-mutant models are sensitive on the basis of downstream proteins that are clients of HSP90, we did not observe any clinical benefit for patients with KRAS mutations. 8 Development of resistance occurs in most patients treated with ALK TKIs.
9,10 AUY922 showed activity in both ALK inhibitor-naive and ALK inhibitor-pretreated patients. Similar prior studies with the single-agent HSP90 inhibitors ganetespib and IPI-504 showed responses in patients with NSCLC who had ALK rearrangement. 11, 12 Responses in EGFR-mutant patients with other HSP90 inhibitors, ganetespib and IPI-504, have been limited. 11, 12 In our study, clinical activity was observed in patients with EGFR mutations, including exon 19 deletions and exon 20 insertions, and in patients with acquired T790M mutations. Differences in EGFR TKI response based on EGFR mutation have been reported previously.
13 Similar to our results described here, an ongoing phase 2 study of AUY922 in patients with NSCLC with exon 20 insertions demonstrated an ORR of 32%. 14 The safety data were similar in patients with advanced solid tumors in the phase 1 trial. 7 Low-grade ocular toxicity was common but effectively managed with dose reductions and dose interruptions. The rate of discontinuation due to AEs was lower in the ALK-rearranged and EGFR<2 strata than in the other groups, indicating that these patients may not have many disease-related comorbidities or that the AEs may have been deemed more tolerable in patients who were benefiting from therapy.
In summary, AUY922 had a manageable safety profile and is active in patients with ALK rearrangement and EGFR mutations, including T790M, which had de novo resistance to EGFR TKIs. Future clinical studies are required to address subsequent overlap between different biomarkers to allocate the right therapy to the right group of patients.
